Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Conditions: Polycythemia Vera

First Posted Date: 2022-03-08

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05269771

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Phase 2

Recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Placebo + standard of care
Drug: Iptacopan (part 1)
Drug: Iptacopan (part 2)
Drug: Iptacopan + placebo

First Posted Date: 2022-03-07

Last Posted Date: 2024-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 240

Registration Number: NCT05268289

Locations: 🇹🇷
Novartis Investigative Site, Talas / Kayseri, Turkey

Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

Recruiting

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Other: Brolucizumab

First Posted Date: 2022-03-04

Last Posted Date: 2024-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 99

Registration Number: NCT05266495

Locations: 🇦🇪
Novartis Investigative Site, Abu Dhabi, United Arab Emirates

Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

Active, not recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Other: Ofatumumab
Other: Ocrelizumab

First Posted Date: 2022-03-04

Last Posted Date: 2024-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 168

Registration Number: NCT05266469

Locations: 🇦🇪
Novartis Investigative Site, Sharjah, United Arab Emirates

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Phase 4

Recruiting

Conditions: Renal Angiomyolipoma

Interventions: Drug: Everolimus

First Posted Date: 2022-02-23

Last Posted Date: 2024-10-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT05252585

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: Midazolam
Drug: Rosuvastatin
Drug: Repaglinide
Drug: Dolutegravir
Drug: Dextromethorphan
Drug: Metformin
Drug: Ganaplacide
Combination Product: Lumefantrine

First Posted Date: 2022-02-11

Last Posted Date: 2022-11-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT05236530

Locations: 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom

Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

Phase 3

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: Secukinumab

First Posted Date: 2022-02-10

Last Posted Date: 2024-02-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT05232864

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, VNM, Vietnam

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Phase 2

Recruiting

Conditions: Age-Related Macular Degeneration

Interventions: Drug: Iptacopan (LNP023)
Drug: Placebo

First Posted Date: 2022-02-09

Last Posted Date: 2024-06-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 146

Registration Number: NCT05230537

Locations: 🇺🇸
Southwest Retina Research Center, Durango, Colorado, United States
🇺🇸
Advanced Research LLC Research, Deerfield Beach, Florida, United States
🇺🇸
Advanced Research LLC, Deerfield Beach, Florida, United States

and more 23 locations

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: Glycopyrronium bromide 25ug
Drug: Placebo
Drug: Glycopyrronium bromide 12.5ug

First Posted Date: 2022-02-03

Last Posted Date: 2024-06-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT05222529

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Managed Access Programs for LNP023, Iptacopan

Conditions: C3 Glomerulopathy (C3G)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

First Posted Date: 2022-02-03

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05222412

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy